NTT Biopharma PIPELINE

Platform Technologies

Brain Delivery Ocular Delivery (Eyedrop Nanoformulation) Nucleic Acid Delivery Oral Peptide Delivery Active Targeting Nanoparticle

Brain Disease

NTT-001 DNA Plasmid (IV Injection for PD)

Cancer Therapy

NTT-002

Ocular Disease

NTT-003 (Eyedrop Formulation for Wet-AMD) ASO (Eyedrop Formulation for Wet-AMD) Therapeutic Peptide (Eyedrop Formulation for Dry-AMD)

Therapeutic Peptide (Eyedrop Formulation for Dry-AMD)

Summary

• A complement C3 inhibitor peptide formulated in the MSN eyedrop nanoformulation can be effectively delivered to the retina, offering a potential non-invasive approach for treating dry age-related macular degeneration (dry AMD).

• In a dry-AMD animal model, the peptide loaded MSN eyedrop formulation demonstrated superior efficacy compared to the commercial intravitreal drug Pegcetacoplan.